SES and CANAL+ Strengthen Partnership With Long-Term Extensions across Western Europe, Central Europe and Africa
SES and CANAL+ have signed new long-term strategic agreements for satellite capacity across three geographies, strengthening the companies’ longstanding partnership and underlining the importance of satellite in delivering premium content to more than 10 million subscribers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005375/en/
SES and CANAL+ Strengthen Partnership With Long-Term Extensions across Western Europe, Central Europe and Africa (Photo: Business Wire)
The multi-transponder contract renewal extends SES and CANAL+ relationship to the end of the decade. It enables SES to support the French pay-TV operator in broadcasting its high-quality bouquets to millions of households around the world via 19.2 degrees East, 23.5 degrees East and 22 degrees West. The new contract represents additional secured backlog of over EUR 230 million and includes options for additional capacity and extensions.
Partners with SES since 1995, CANAL+ will continue to utilise satellite capacity to broadcast bouquets of channels in ultra high definition (UHD), high definition (HD) and standard definition (SD) for its various businesses to reach over 10 million TV households via SES’s orbital positions:
- ASTRA’s prime orbital position 19.2 degrees East for distribution of the CANAL+ premium pay-tv bouquet in France;
- ASTRA’s prime orbital position 19.2 degrees East for distribution of TNTSAT, the free-to-view digital terrestrial television satellite television offering in France;
- ASTRA’s prime orbital position 23.5 degrees East and 19.2 degrees East for CANAL+’s subsidiary, the Luxembourg-based M7 which operates a series of independent pay-TV platforms across the Benelux and Central European region;
- SES-4 at 22 degrees West for distribution of the CANAL+ Afrique bouquet across Africa
“Extending our partnership with SES was a natural choice, since we have a long and successful partnership in delivering superior quality video experiences to diverse audiences around the world. This agreement across three orbital slots demonstrates that satellite is at heart of our pay-tv operations throughout the world. We look forward to many more years of working together to ensure we reach the widest possible TV audiences,” said Jacques du Puy, CEO, CANAL+ International.
“CANAL+ is an iconic global company and brand that evokes quality, innovation and outstanding content and is among our longest standing and most valued customers. We are incredibly proud of the trust that CANAL+ has placed in SES and it underscores our mutual belief in the power of satellite to broadcast the best content, in the highest definition to the broadest base of subscribers on a global basis. This agreement ensures that we will continue to serve the neighbourhoods that we have built together for the next decade and beyond.” said Steve Collar, CEO at SES.
Follow us on:
Social Media
Blog
Media Library
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005375/en/
Contact information
For further information:
Suzanne Ong
External Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Study Suggests Critical Link Between Residual FLT3 -ITD Mutations in Remission and Post-Transplant Outcomes in AML8.5.2024 16:00:00 CEST | Press release
A groundbreaking research study,1 sequencing DNA samples from the Pre-MEASURE study2 strongly indicates that the detection of residual FLT3 internal tandem duplication (ITD) mutations in the blood of adult subjects with acute myeloid leukemia (AML) in first complete remission (CR) is associated with worse outcomes after post allogeneic hematopoietic cell transplant (HCT). This follow-up study performed measurable residual disease (MRD) testing on DNA of 537 subjects with FLT3-ITD AML from the Pre-MEASURE study using Invivoscribe’s RUO FLT3 ITD MRD Assay kit and bioinformatics software. Its findings underscore the likely significance of residual FLT3-ITD in first CR in predicting relapse and mortality post-transplant. A key finding from this research study was that AML subjects with residual FLT3-ITD detected prior to allogeneic HCT trended towards elevated risk of relapse and mortality post-transplant, with a dose-dependent correlation within this study population. Dr. Hourigan, Direct
RunPod Raises $20M in Seed Funding Co-led by Intel Capital and Dell Technologies Capital8.5.2024 15:07:00 CEST | Press release
RunPod, the launchpad that empowers developers to deploy custom full-stack AI applications, today announced it raised $20M in Seed funding, co-led by Intel Capital and Dell Technologies Capital with participation from Julien Chaummond, Nat Friedman, and Adam Lewis. In conjunction with the financing, Mark Rostick, Vice President and Senior Managing Director at Intel Capital, will join RunPod’s board of directors. RunPod is a globally distributed GPU cloud computing service for training, deploying, and scaling AI models. Using RunPod’s two core products, GPU Cloud and Serverless, developers can spin up an on-demand GPU instance in a few clicks and create autoscaling API endpoints for scaling inference on AI models in production. “The ability to create and deploy AI applications at scale will be paramount to their adoption and utilization,” said Amjad Masad, RunPod investor. “The RunPod team has clearly prioritized the developer experience to create an elegant solution that enables indivi
Tigo Energy Delivers Most Powerful Solar MLPE for High-Wattage and Bifacial Modules8.5.2024 15:00:00 CEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the newest additions to the Tigo Flex MLPE product family, the Tigo TS4-X line. Designed to serve the commercial and industrial (C&I) as well as utility solar markets, Tigo TS4-X products support the latest high-power solar modules, up to 800W. Members of the TS4-X product family feature compatibility with Pure Signal™ technology in Tigo RSS Transmitters and offer a Multi-Factor Rapid Shutdown (MFRS) option with redundant safety signaling for solar systems serving the food and pharmaceutical cold-chain sectors, or other energy-critical applications. The new devices pair with an industry-leading list of third-party solar inverters to deliver design and installation flexibility for solar installers and engineering, procurement, and construction specialists (EPCs). As Levelized Cost Of Energy (LCOE) continues to drive the large-scale solar sectors, the TS4-X product lin
Cyolo Partners with Dragos to Unveil Holistic Secure Remote Access Solution for Critical Infrastructure8.5.2024 14:30:00 CEST | Press release
Cyolo, the secure remote access company for operational technology (OT) and industrial control systems (ICS), today announced a strategic partnership with Dragos, a global leader in cybersecurity for ICS/OT. Under the umbrella of Cyolo’s CyoloVerse partner program, Cyolo's PRO Secure Remote Access Platform will work with Dragos’s industry-leading OT cybersecurity platform. This collaboration will provide organizations with a robust and interoperable solution to protect their critical infrastructure against cyber threats. New technology implementations in ICS/OT environments pose unique risks for critical infrastructure. Today’s risks include lack of support for modern authentication or connectivity methods in traditional environments, connecting existing infrastructure with highly vulnerable end-of-life operating systems, or risk of breaches from third-party remote access. This interoperability is designed to provide OT customers visibility and management of their asset inventory and e
John Patton, Head of Kindeva Drug Delivery’s Scientific Advisory Board, Named Winner of RDD Conference’s Charles G. Thiel Award8.5.2024 14:00:00 CEST | Press release
At the recent Respiratory Drug Delivery (RDD) Conference, John Patton, Ph.D., biotechnology scientist and entrepreneur and Head of the Scientific Advisory Board (SAB) for Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, was announced as the winner of the Charles G. Thiel Award. This prestigious award is given once every two years at RDD Conferences to one scientist who has been voted by his or her peers to have pioneered significant developments in one or more aspects of the science and technology surrounding respiratory drug delivery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508931671/en/ Biotechnology scientist and entrepreneur and Kindeva Drug Delivery’s Head of the Scientific Advisory Board, John Patton (second from the left), was named the winner of the Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery at this year’s Respiratory Drug